252 related articles for article (PubMed ID: 32681658)
1. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
Elhadad S; Chapin J; Copertino D; Van Besien K; Ahamed J; Laurence J
Clin Exp Immunol; 2021 Jan; 203(1):96-104. PubMed ID: 32681658
[TBL] [Abstract][Full Text] [Related]
2. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.
Elhadad S; Redmond D; Huang J; Tan A; Laurence J
Clin Exp Immunol; 2023 Jul; 213(2):252-264. PubMed ID: 37191586
[TBL] [Abstract][Full Text] [Related]
3. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Rambaldi A; Gritti G; Micò MC; Frigeni M; Borleri G; Salvi A; Landi F; Pavoni C; Sonzogni A; Gianatti A; Binda F; Fagiuoli S; Di Marco F; Lorini L; Remuzzi G; Whitaker S; Demopulos G
Immunobiology; 2020 Nov; 225(6):152001. PubMed ID: 32943233
[TBL] [Abstract][Full Text] [Related]
4. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
5. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Khaled SK; Claes K; Goh YT; Kwong YL; Leung N; Mendrek W; Nakamura R; Sathar J; Ng E; Nangia N; Whitaker S; Rambaldi A;
J Clin Oncol; 2022 Aug; 40(22):2447-2457. PubMed ID: 35439028
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
7. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.
Dudler T; Yaseen S; Cummings WJ
Front Immunol; 2023; 14():1297352. PubMed ID: 38022610
[TBL] [Abstract][Full Text] [Related]
9. The alternative pathway of complement and the thrombotic microangiopathies.
Teoh CW; Riedl M; Licht C
Transfus Apher Sci; 2016 Apr; 54(2):220-31. PubMed ID: 27160864
[TBL] [Abstract][Full Text] [Related]
10. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies.
Trojnar E; Józsi M; Szabó Z; Réti M; Farkas P; Kelen K; Reusz GS; Szabó AJ; Garam N; Mikes B; Sinkovits G; Mező B; Csuka D; Prohászka Z
Front Immunol; 2019; 10():240. PubMed ID: 30858847
[TBL] [Abstract][Full Text] [Related]
11. Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies.
Elhadad S; Redmond D; Tan A; Huang J; Rodriguez BL; Racine-Brzostek SE; Subrahmanian S; Ahamed J; Laurence J
Thromb Res; 2023 May; 225():47-56. PubMed ID: 37001283
[TBL] [Abstract][Full Text] [Related]
12. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation.
Qi J; Wang J; Chen J; Su J; Tang Y; Wu X; Ma X; Chen F; Ruan C; Zheng XL; Wu D; Han Y
Ann Hematol; 2017 Nov; 96(11):1849-1855. PubMed ID: 28801815
[TBL] [Abstract][Full Text] [Related]
13. Narsoplimab for severe transplant-associated thrombotic microangiopathy.
Pandrowala A; Ganatra P; Krishnan VP; Sharma AN; Chavan S; Bodhanwala M; Agarwal B; Hiwarkar P
Thromb J; 2023 Mar; 21(1):26. PubMed ID: 36915123
[TBL] [Abstract][Full Text] [Related]
14. Thrombotic Microangiopathy Syndromes-Common Ground and Distinct Frontiers.
Hanna RM; Henriksen K; Kalantar-Zadeh K; Ferrey A; Burwick R; Jhaveri KD
Adv Chronic Kidney Dis; 2022 Mar; 29(2):149-160.e1. PubMed ID: 35817522
[TBL] [Abstract][Full Text] [Related]
15. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
16. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Jodele S; Licht C; Goebel J; Dixon BP; Zhang K; Sivakumaran TA; Davies SM; Pluthero FG; Lu L; Laskin BL
Blood; 2013 Sep; 122(12):2003-7. PubMed ID: 23814021
[TBL] [Abstract][Full Text] [Related]
17. Interferon-complement loop in transplant-associated thrombotic microangiopathy.
Jodele S; Medvedovic M; Luebbering N; Chen J; Dandoy CE; Laskin BL; Davies SM
Blood Adv; 2020 Mar; 4(6):1166-1177. PubMed ID: 32208488
[TBL] [Abstract][Full Text] [Related]
18. C5b-9 and MASP2 deposition in skin and bone marrow microvasculature characterize hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Elhadad S; Chadburn A; Magro C; Van Besien K; Roberson EDO; Atkinson JP; Terry H; Greenberg J; Reid W; Chapin J; Copertino D; Geramfard S; Rodriguez LB; Orfali N; Gerghis U; Shore T; Mayer S; Ahamed J; Laurence J
Bone Marrow Transplant; 2022 Sep; 57(9):1445-1447. PubMed ID: 35661836
[No Abstract] [Full Text] [Related]
19. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
20. Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies.
Farkas P; Csuka D; Mikes B; Sinkovits G; Réti M; Németh E; Rácz K; Madách K; Gergely M; Demeter J; Prohászka Z
Immunobiology; 2017 Feb; 222(2):119-127. PubMed ID: 27771173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
